Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

ClinicalTrials.gov ID: NCT04595370

Public ClinicalTrials.gov record NCT04595370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease

Study identification

NCT ID
NCT04595370
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
153 participants

Conditions and interventions

Interventions

  • AZD9977 Drug
  • Dapagliflozin Drug

Drug

Eligibility (public fields only)

Age range
21 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 25, 2021
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update posted
Nov 18, 2024

2021 – 2023

United States locations

U.S. sites
26
U.S. states
11
U.S. cities
25
Facility City State ZIP Site status
Research Site Beverly Hills California 90211
Research Site Fountain Valley California 92708
Research Site Northridge California 91324
Research Site South Gate California 90280
Research Site Hialeah Florida 33016
Research Site Homestead Florida 33032
Research Site Jacksonville Florida 32216
Research Site Miami Florida 33155
Research Site Ocala Florida 34474
Research Site Tampa Florida 33603
Research Site Augusta Georgia 30904
Research Site Columbus Georgia 31904
Research Site Baltimore Maryland 21287
Research Site Methuen Massachusetts 01844
Research Site St Louis Missouri 63136
Research Site The Bronx New York 10455
Research Site New Bern North Carolina 28562
Research Site Rapid City South Dakota 57701
Research Site Memphis Tennessee 38119
Research Site Houston Texas 77087
Research Site Houston Texas 77099
Research Site Kingwood Texas 77339
Research Site McKinney Texas 75069
Research Site San Antonio Texas 78207
Research Site Sherman Texas 75092
Research Site Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04595370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04595370 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →